Payload Information
General Information of This Payload
| Payload ID | PAY0ZJMHY |
|||||
|---|---|---|---|---|---|---|
| Name | Glucuronyl-monomethyl-auristatin E (MMAU) |
|||||
| Synonyms |
Glucuronyl-monomethyl-auristatin E (MMAU)
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
EGFR-MMAU ADC [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 84.20% | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
MMAU ADCs (3 mg/kg, intravenously four times at seven day intervals) induces efficient tumor cell killing in cell line-derived models of HSC-2 cells with EGFR expression with high expression.
|
||||
| In Vivo Model | HSC-2 CDX model | ||||
| In Vitro Model | Oral cavity squamous cell carcinoma | HSC-2 cells | CVCL_1287 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.30% | Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
MMAU ADCs (10 mg/kg, intravenously four times at seven day intervals) induces efficient tumor cell killing in cell line-derived models of HSC-2 cells with EGFR expression with high expression.
|
||||
| In Vivo Model | HSC-2 CDX model | ||||
| In Vitro Model | Oral cavity squamous cell carcinoma | HSC-2 cells | CVCL_1287 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
25 pM
|
Low EGFR expression (EGFR+) | ||
| Method Description |
Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO2 for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
|
||||
| In Vitro Model | Non-small cell lung carcinoma | NCI-H522 cells | CVCL_1567 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
30 pM
|
High EGFR expression (EGFR+++) | ||
| Method Description |
Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO2 for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
GLK-33 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.14 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.21 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | MOLM-13 cells | CVCL_2119 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.24 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.4 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | KG-1 cells | CVCL_0374 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.7 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Acute myeloid leukemia | OCI-M1 cells | CVCL_2149 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
725 nM
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Chronic myelogenous leukemia | K-562 cells | CVCL_0004 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 nM | Negative CD33 expression (CD33-) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 nM | Negative CD33 expression (CD33-) | ||
| Method Description |
GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
References